Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals

Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325

The fundamental role of epigenetic events in cancer

Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648

The Epigenomics of Cancer

Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515

Epigenetics in human disease and prospects for epigenetic therapy

Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232

Histone deacetylases (HDACs): characterization of the classical HDAC family

RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114

A decade of exploring the cancer epigenome—biological and translational implications

Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871

Anticancer activities of histone deacetylase inhibitors

Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919

Epigenetics in cancer

Sharma, S., Kelly, T. K., & Jones, P. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp220 · Cited by 2,637

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515

Epigenetic Determinants of Cancer

Baylin, S. B., & Jones, P. A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019505 · Cited by 1,226

DNA methylation and chromatin modification

Ng, H.-H., & Adrian, B. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80024-0 · Cited by 648

Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer

Topper, M. J., Vaz, M., Chiappinelli, K. B., DeStefano Shields, C. E., Niknafs, N., Yen, R.-W. C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.022 · Cited by 537

CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS

Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K., & Benz, C. C. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095825 · Cited by 494

DNA methylation and chromatin – unraveling the tangled web

Robertson, K. D. (2002) · Oncogene · doi:10.1038/sj.onc.1205609 · Cited by 471

Histone H3 Lysine 4 Demethylation Is a Target of Nonselective Antidepressive Medications

Lee, M. G., Wynder, C., Schmidt, D. M., McCafferty, D. G., & Shiekhattar, R. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.05.004 · Cited by 438

The emerging role of epigenetic therapeutics in immuno-oncology

Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433

N-CoR Mediates DNA Methylation-Dependent Repression through a Methyl CpG Binding Protein Kaiso

Yoon, H.-G., Chan, D. W., Reynolds, A. B., Qin, J., & Wong, J. (2003) · Molecular Cell · doi:10.1016/j.molcel.2003.08.008 · Cited by 408

Double Strand Breaks Can Initiate Gene Silencing and SIRT1-Dependent Onset of DNA Methylation in an Exogenous Promoter CpG Island

O'Hagan, H. M., Mohammad, H. P., & Baylin, S. B. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000155 · Cited by 386

Inhibition of SIRT1 Reactivates Silenced Cancer Genes without Loss of Promoter DNA Hypermethylation

Pruitt, K., Zinn, R. L., Ohm, J. E., McGarvey, K. M., Kang, S.-H. L., Watkins, D. N., Herman, J. G., & Baylin, S. B. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020040 · Cited by 387

DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats

Brocks, D., Schmidt, C. R., Daskalakis, M., Jang, H. S., Shah, N. M., Li, D., Li, J., Zhang, B., Hou, Y., Laudato, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3889 · Cited by 339

Epigenetics of endometriosis

Guo, S.-W. (2009) · Molecular Human Reproduction · doi:10.1093/molehr/gap064 · Cited by 328

Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells

Coffee, B., Zhang, F., Warren, S. T., & Reines, D. (1999) · Nature Genetics · doi:10.1038/8807 · Cited by 325

Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors

Magner, W. J., Kazim, A. L., Stewart, C., Romano, M. A., Catalano, G., Grande, C., Keiser, N., Santaniello, F., & Tomasi, T. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.7017 · Cited by 294

Valproate Induces widespread epigenetic reprogramming which involves demethylation of specific genes

Milutinovic, S., D'Alessio, A. C., Detich, N., & Szyf, M. (2007) · Carcinogenesis · doi:10.1093/carcin/bgl167 · Cited by 256

Epigenetics as a mechanism driving polygenic clinical drug resistance

Glasspool, R. M., Teodoridis, J. M., & Brown, R. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603024 · Cited by 236

Pharmacology of 5-Aza-2′-deoxycytidine (decitabine)

Momparler, R. L. (2005) · Seminars in Hematology · doi:10.1053/j.seminhematol.2005.05.002 · Cited by 231

The Ski protein family is required for MeCP2-mediated transcriptional repression.

Kokura, K., Kaul, S. C., Wadhwa, R., Nomura, T., Khan, M. M., Shinagawa, T., Yasukawa, T., Colmenares, C., & Ishii, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105747200 · Cited by 222

Synergistic Effect of Histone Hyperacetylation and DNA Demethylation in the Reactivation of the FMR1 Gene

Chiurazzi, P., Grazia Pomponi, M., Pietrobono, R., Bakker, C. E., Neri, G., & Oostra, B. A. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.12.2317 · Cited by 217

Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A.

Milhem, M., Mahmud, N., Lavelle, D., Araki, H., DeSimone, J., Saunthararajah, Y., & Hoffman, R. (2004) · Blood · doi:10.1182/blood-2003-07-2431 · Cited by 195

The role of AUF1 in regulated mRNA decay

Gratacós, F. M., & Brewer, G. (2010) · WIREs RNA · doi:10.1002/wrna.26 · Cited by 193

Zebularine: a new drug for epigenetic therapy

Yoo, C. B., Cheng, J. C., & Jones, P. A. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320910 · Cited by 191

Maternal licking regulates hippocampal glucocorticoid receptor transcription through a thyroid hormone–serotonin–NGFI-A signalling cascade

Hellstrom, I. C., Dhir, S. K., Diorio, J. C., & Meaney, M. J. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2012.0223 · Cited by 171

Epigenetic cancer therapy: rationales, targets and drugs

Rius, M., & Lyko, F. (2012) · Oncogene · doi:10.1038/onc.2011.601 · Cited by 157

Epigenetic regulation of female puberty

Lomniczi, A., Wright, H., & Ojeda, S. R. (2015) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.08.003 · Cited by 136

ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor

Fan, J., Yin, W.-J., Lu, J.-S., Wang, L., Wu, J., Wu, F.-Y., Di, G.-H., Shen, Z.-Z., & Shao, Z.-M. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0354-x · Cited by 129

Primary hepatocyte cultures for pharmaco-toxicological studies: at the busy crossroad of various anti-dedifferentiation strategies

Fraczek, J., Bolleyn, J., Vanhaecke, T., Rogiers, V., & Vinken, M. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0983-3 · Cited by 119

Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes

Garcia‐Manero, G., Montalban‐Bravo, G., Berdeja, J. G., Abaza, Y., Jabbour, E., Essell, J., Lyons, R. M., Ravandi, F., Maris, M., Heller, B., et al. (2017) · Cancer · doi:10.1002/cncr.30533 · Cited by 104

PRDM5 Identified as a Target of Epigenetic Silencing in Colorectal and Gastric Cancer

Watanabe, Y., Toyota, M., Kondo, Y., Suzuki, H., Imai, T., Ohe-Toyota, M., Maruyama, R., Nojima, M., Sasaki, Y., Sekido, Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0305 · Cited by 89

Environmental regulation of the neural epigenome

Caldji, C., Hellstrom, I. C., Zhang, T.-Y., Diorio, J., & Meaney, M. J. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.032 · Cited by 82

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study

Garcia-Manero, G., Abaza, Y., Takahashi, K., Medeiros, B. C., Arellano, M., Khaled, S. K., Patnaik, M., Odenike, O., Sayar, H., Tummala, M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018027409 · Cited by 78

SUV39H1 interacts with AML1 and abrogates AML1 transactivity: AML1 is methylated in vivo.

Chakraborty, S., Sinha, K. K., Senyuk, V., & Nucifora, G. (2003) · Oncogene · doi:10.1038/sj.onc.1206600 · Cited by 71

Sp1/Sp3 and DNA-methylation contribute to basal transcriptional activation of human podoplanin in MG63 versus Saos-2 osteoblastic cells

Hantusch, B., Kalt, R., Krieger, S., Puri, C., & Kerjaschki, D. (2007) · BMC Molecular Biology · doi:10.1186/1471-2199-8-20 · Cited by 63

Histone modifications as a pathogenic mechanism of colorectal tumorigenesis

Gargalionis, A. N., Piperi, C., Adamopoulos, C., & Papavassiliou, A. G. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.05.002 · Cited by 53

Suppression of DPYD expression in RKO Cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression

Zhang, X., Soong, R., Wang, K., Li, L., Davie, J. R., Guarcello, V., & Diasio, R. B. (2007) · Biochemistry and Cell Biology · doi:10.1139/o07-009 · Cited by 21